Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
The cannabinoid CB1 receptor antagonist SR141716A increases norepinephrineoutflow in the rat anterior hypothalamus
Autore:
Tzavara, ET; Perry, KW; Rodriguez, DE; Bymaster, FP; Nomikos, GG;
Indirizzi:
Eli Lilly & Co, Lilly Corp Ctr, Neurosci Discovery Res, Indianapolis, IN 46285 USA Eli Lilly & Co Indianapolis IN USA 46285 Res, Indianapolis, IN 46285 USA
Titolo Testata:
EUROPEAN JOURNAL OF PHARMACOLOGY
fascicolo: 3, volume: 426, anno: 2001,
pagine: R3 - R4
SICI:
0014-2999(20010831)426:3<R3:TCCRAS>2.0.ZU;2-T
Fonte:
ISI
Lingua:
ENG
Soggetto:
RELEASE; BRAIN;
Keywords:
microdialysis; norepinephrine; SR141716A;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
8
Recensione:
Indirizzi per estratti:
Indirizzo: Nomikos, GG Eli Lilly & Co, Lilly Corp Ctr, Neurosci Discovery Res, Indianapolis, IN 46285 USA Eli Lilly & Co Indianapolis IN USA 46285 apolis, IN 46285 USA
Citazione:
E.T. Tzavara et al., "The cannabinoid CB1 receptor antagonist SR141716A increases norepinephrineoutflow in the rat anterior hypothalamus", EUR J PHARM, 426(3), 2001, pp. R3-R4

Abstract

The effects of the selective cannabinoid CB1 receptor antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide-hydrochloride (SR141716A) on extracellular concentrations of norepinephrine and 5-hydroxytryptamine (5-HT) were assessed by in vivo microdialysis in the anterior hypothalamus of freely moving rats. SR14716A (0.3, 1, 3 mg/kg, i.p.) dose-dependently increased norepinephrine efflux to about300% of baseline, without affecting 5-HT levels. This increase in norepinephrine outflow could play an important role in the pharmacological and potentially therapeutic actions of SR141716A. (C) 2001 Published by Elsevier Science B.V.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/04/20 alle ore 06:36:26